Leukemia

“A life is not important except in the impact it has on other lives.”

As suspected, the average early mortality rate improved overall during the study period. But while evaluating the data, researchers noticed something interesting about the difference in early mortality at the NCI-designated cancer centers compared to non-NCI-designated cancer centers.

Tavalisse (fostamatinib) was granted approval by the Food and Drug Administration (FDA) for patients with chronic immune thrombocytopenia (ITP) after they had an insufficiencent response to another therapy.

A new drug combination bested current standard of care in a clinical trial.

The Food and Drug Administration (FDA) granted duvelisib a priority review to a new drug application (NDA) for full approval to treat patients who have relapsed or refractory chronic lymphocytic leukemia or small lymphocytic leukemia (CLL/SLL). The FDA also granted an accelerated approval for the treatment of patients with relapsed or refractory follicular lymphoma.

After extensive chemo treatment was completed, intended to kill all the leukemic cells in my sick body, a courier was sent to Israel to collect the harvested marrow from my donor, and immediately fly it back to the U.S. where I was to be infused.

The potential approval offers hope to the rare blood cancer, which currently has no standard of care treatment protocol.

Blincyto (blinatumomab) was granted approval by the Food and Drug Administration (FDA) to treat patients who have B-cell precursor acute lymphoblastic leukemia (ALL), who are in remission but still have minimal residual disease (MRD).

Tasigna (nilotinib) was granted Food and Drug Administration (FDA) approval, to be used in the first- and second-line setting for pediatric patients 1 year old or older who have Philadelphia chromosome–positive chronic myeloid leukemia in the chronic phase (Ph+ CML-CP). 

The time has finally come when researchers have found a way to harness the immune system and use it to fight blood cancers.